Semaglutide Side Effects

The most common semaglutide side effects

Wegovy's adverse-reaction table reports nausea in 44% of participants, diarrhea in 30%, vomiting in 24%, constipation in 24%, and abdominal pain in 20%, compared with 16%, 16%, 6%, 11%, and 10% with placebo. Headache, fatigue, dyspepsia, dizziness, bloating, belching, and hypoglycemia in type 2 diabetes are also listed reactions.

Symptoms that need prompt attention

Wegovy and Ozempic labels warn about pancreatitis, gallbladder disease, acute kidney injury related to volume depletion, severe GI reactions, and serious hypersensitivity. Severe persistent abdominal pain, repeated vomiting, inability to retain fluids, fainting, or signs of an allergic reaction should move from routine symptom tracking to prompt clinical assessment.

Diabetes changes the safety conversation

Ozempic labeling says people with a history of diabetic retinopathy should be monitored for progression. New or meaningful visual changes should be reported promptly. Hypoglycemia risk rises when semaglutide is used with insulin or an insulin secretagogue, so the diabetes regimen needs clinician review rather than self-adjustment.

Diabetes adds two specific questions

Ozempic labeling warns that people with a history of diabetic retinopathy should be monitored for progression. New or meaningful visual changes should go to the clinical team promptly, particularly for a person with diabetes.

Hypoglycemia risk rises when semaglutide is used with insulin or an insulin secretagogue. The care team may need to reassess those medicines. A reader should not reduce or stop another diabetes medicine alone.

Procedures and pregnancy plans need a medication review

GLP-1 receptor agonists delay gastric emptying, which matters for some oral medicines and for planned procedures involving anesthesia or deep sedation. Tell the relevant clinicians about the medication in advance.

Product labeling also contains pregnancy-related guidance. A safe page directs readers to the current label and prescriber instead of giving a generic stop or start plan.

Do not flatten approved and compounded products

FDA says compounded GLP-1 products do not undergo FDA review for safety, effectiveness, or quality before they are marketed. FDA has also described dosing errors and formulation differences with compounded semaglutide products.

That means a lower-cost vial or an unfamiliar instruction sheet cannot be treated as an approved pen with a different price. Verify the exact product with the prescriber and dispensing pharmacy.

What the cited sources establish

Semaglutide safety requires the product label that matches the situation. Wegovy supplies weight-management safety context, Ozempic adds diabetes, retinopathy, and hypoglycemia-interaction context, and STEP 1 provides obesity-trial reporting. Common GI symptoms do not erase the labels' warnings about dehydration, pancreatitis, gallbladder disease, severe reactions, or hypersensitivity.

Common GI effects and urgent symptoms should be separated early. Record severity, duration, hydration, urine output, associated pain, diabetes medicines, and any visual change rather than trying to classify the cause at home. Ozempic's retinopathy warning makes eye history relevant in diabetes care, while insulin or sulfonylurea use changes the low-glucose discussion. Compounded-product instructions need their own product-level verification.

The Wegovy reaction rates give a concrete picture of what participants reported, while the warning sections identify symptom patterns that deserve faster assessment. Repeated vomiting and reduced fluid intake can become a dehydration and kidney-risk issue. Severe abdominal pain needs evaluation for causes named in the label. In diabetes care, new visual changes and low-glucose symptoms add separate paths for clinical review because Ozempic labeling and combination therapy provide different context.

Questions that change the next review

For a semaglutide symptom review, document timing, severity, hydration, ability to eat, urine output, other diabetes medicines, and any new visual change. That gives the care team information to evaluate the pattern and to consider retinopathy or hypoglycemia context where relevant, without asking the reader to diagnose it.

A useful symptom report includes the exact semaglutide product, severity and timing, hydration, abdominal symptoms, diabetes medicines, and visual changes. That gives the clinician the information the labels make relevant.

Product details that still need verification

This page does not identify the cause of pain, vomiting, or vision change, and it does not authorize a product switch or dose change. Compounded semaglutide may have different formulation and instructions from approved products, so an approved label cannot be treated as a conversion guide for an unfamiliar vial.

Use the exact product label because indications and presentations differ. Severe abdominal pain, repeated vomiting, dehydration, and allergic symptoms are not routine troubleshooting questions. Diabetes medicines and a history of diabetic retinopathy change the monitoring conversation. Compounded semaglutide is not FDA-approved and may have different instructions. Use the exact product label and report serious, persistent, or changing symptoms to the clinical team. Avoid self-directed medication changes or assumptions about compounded product equivalence.

Use the current product label and prompt clinical care for urgent symptoms or medication changes.